Skip to main content

Advertisement

SpringerLink
Log in

Outpatient parenteral antimicrobial therapy with ceftriaxone, a review

  • Review Article
  • Published:
International Journal of Clinical Pharmacy Aims and scope Submit manuscript

Abstract

Background More than 30 years since it was developed for clinical use, the third-generation cephalosporin ceftriaxone remains the most commonly used agent for outpatient parental antimicrobial therapy (OPAT). Recent antimicrobial stewardship programmes have tended to restrict ceftriaxone use in hospitals to control antibiotic resistance and outbreaks of Clostridium difficle infection (CDI). Considering the expansion of OPAT programmes both in the UK and worldwide, revisiting the role of ceftriaxone in OPAT in the context of changing antimicrobial prescribing practices is timely. Aim of the review To identify the evidence base for OPAT, review current and historical data on indications for, and safety of ceftriaxone within the OPAT setting, and to provide some perspectives on the future role of ceftriaxone. Method We searched PubMed and Scopus for articles published in English, and hand searched reference lists. We also conducted a complementary descriptive analysis of prospectively acquired data on the use of ceftriaxone in more than 1,300 OPAT episodes over a 10-year period in our UK centre. Results Ceftriaxone has an excellent safety profile in the OPAT setting, and its broad spectrum of activity makes it an established agent in a wide range of clinical infection syndromes, such as skin and soft-tissue infection, bone and joint infection, streptococcal endocarditis and several others. Intriguingly, in contrast to the inpatient setting, liberal use of ceftriaxone in OPAT has not been strongly linked to CDI, suggesting additional patient and environmental factors may be important in mediating CDI risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Newton GG, Abraham EP, Cephalosporin C. a new antibiotic containing sulphur and D-alpha-aminoadipic acid. Nature. 1955;175(4456):548.

    Article  PubMed  CAS  Google Scholar 

  2. Abraham EP. Cephalosporins 1945–1986. Drugs. 1987;34(Suppl 2):1–14.

    Article  PubMed  CAS  Google Scholar 

  3. Reiner R, Weiss U, Brombacher U, Lanz P, Montavon M, Furlenmeier A, et al. Ro 13-9904/001, a novel potent and long-acting parenteral cephalosporin. J Antibiot (Tokyo). 1980;33(7):783–6.

    Article  CAS  Google Scholar 

  4. Esposito S. Parenteral cephalosporin therapy in ambulatory care: advantages and disadvantages. Drugs. 2000;59(Suppl 3):19–28. (discussion 47–49).

    Article  PubMed  CAS  Google Scholar 

  5. Esposito S, Noviello S, Leone S, Tice A, Seibold G, Nathwani D, et al. Outpatient parenteral antibiotic therapy (OPAT) in different countries: a comparison. Int J Antimicrob Agents. 2004;24(5):473–8.

    Article  PubMed  CAS  Google Scholar 

  6. Paladino JA, Poretz D. Outpatient parenteral antimicrobial therapy today. Clin Infect Dis. 2010;51(Suppl 2):S198–208.

    Article  PubMed  Google Scholar 

  7. Eron LJ, Park CH, Hixon DL, Goldenberg RI, Poretz DM. Ceftriaxone therapy of bone and soft tissue infections in hospital and outpatient settings. Antimicrob Agents Chemother. 1983;23(5):731–7.

    Article  PubMed  CAS  Google Scholar 

  8. Poretz DM. Outpatient parenteral antibiotic therapy. Int J Antimicrob Agents. 1995;5(1):9–12.

    Article  PubMed  CAS  Google Scholar 

  9. Bernstein Hahn L, Barclay CA, Iribarren MA, Traballi CA. Ceftriaxone, a new parenteral cephalosporin, in the treatment of urinary tract infections. Chemotherapy. 1981;27(Suppl 1):75–9.

    Article  PubMed  Google Scholar 

  10. Eichmann A, Weidmann G, Havas L. One-dose treatment of acute uncomplicated gonorrhoea of male patients with ceftriaxone Ro 13-9904, a new parenteral cephalosporin. A dose-range finding pilot study using doses of 500, 250, 125 and 50 mg respectively, in descending order. Chemotherapy. 1981;27(Suppl 1):62–9.

    Article  PubMed  Google Scholar 

  11. Baumgartner JD, Glauser MP. Single daily dose treatment of severe refractory infections with ceftriaxone. Cost savings and possible parenteral outpatient treatment. Arch Intern Med. 1983;143(10):1868–73.

    Article  PubMed  CAS  Google Scholar 

  12. Handsfield HH, Murphy VL. Comparative study of ceftriaxone and spectinomycin for treatment of uncomplicated gonorrhoea in men. Lancet. 1983;2(8341):67–70.

    Article  PubMed  CAS  Google Scholar 

  13. Poretz DM, Woolard D, Eron LJ, Goldenberg RI, Rising J, Sparks S. Outpatient use of ceftriaxone: a cost-benefit analysis. Am J Med. 1984;77(4C):77–83.

    PubMed  CAS  Google Scholar 

  14. Tice AD. Once-daily ceftriaxone outpatient therapy in adults with infections. Chemotherapy. 1991;37(Suppl 3):7–10.

    Article  PubMed  Google Scholar 

  15. Tice AD. International outpatient parenteral antimicrobial therapy. Int J Clin Pract Suppl. 2000;115:26.

    PubMed  Google Scholar 

  16. Torok ME, Chapman AL, Lessing MP, Sanderson F, Seaton RA. Outpatient parenteral antimicrobial therapy: recent developments and future prospects. Curr Opin Investig Drugs. 2010;11(8):929–39.

    PubMed  CAS  Google Scholar 

  17. Russo TA, Cook S, Gorbach SL. Intramuscular ceftriaxone in home parenteral therapy. Antimicrob Agents Chemother. 1988;32(9):1439–40.

    Article  PubMed  CAS  Google Scholar 

  18. Chapman AL, Dixon S, Andrews D, Lillie PJ, Bazaz R, Patchett JD. Clinical efficacy and cost-effectiveness of outpatient parenteral antibiotic therapy (OPAT): a UK perspective. J Antimicrob Chemother. 2009;64(6):1316–24.

    Article  PubMed  CAS  Google Scholar 

  19. Caplan GA, Ward JA, Brennan NJ, Coconis J, Board N, Brown A. Hospital in the home: a randomised controlled trial. Med J Aust. 1999;170(4):156–60.

    PubMed  CAS  Google Scholar 

  20. Corwin P, Toop L, McGeoch G, Than M, Wynn-Thomas S, Wells JE, et al. Randomised controlled trial of intravenous antibiotic treatment for cellulitis at home compared with hospital. Bmj. 2005;330(7483):129.

    Article  PubMed  Google Scholar 

  21. Shepperd S, Doll H, Angus RM, Clarke MJ, Iliffe S, Kalra L, et al. Admission avoidance hospital at home. Cochrane Database Syst Rev. 2008;(4):CD007491.

  22. Nathwani D, Tice A. Ambulatory antimicrobial use: the value of an outcomes registry. J Antimicrob Chemother. 2002;49(1):149–54.

    Article  PubMed  CAS  Google Scholar 

  23. Wynn M, Dalovisio JR, Tice AD, Jiang X. Evaluation of the efficacy and safety of outpatient parenteral antimicrobial therapy for infections with methicillin-sensitive Staphylococcus aureus. South Med J. 2005;98(6):590–5.

    Article  PubMed  Google Scholar 

  24. Matthews PC, Conlon CP, Berendt AR, Kayley J, Jefferies L, Atkins BL, et al. Outpatient parenteral antimicrobial therapy (OPAT): is it safe for selected patients to self-administer at home? A retrospective analysis of a large cohort over 13 years. J Antimicrob Chemother. 2007;60(2):356–62.

    Article  PubMed  CAS  Google Scholar 

  25. Esposito S, Leone S, Noviello S, Ianniello F, Fiore M, Russo M, et al. Outpatient parenteral antibiotic therapy for bone and joint infections: an Italian multicenter study. J Chemother. 2007;19(4):417–22.

    PubMed  CAS  Google Scholar 

  26. Mackintosh CL, White HA, Seaton RA. Outpatient parenteral antibiotic therapy (OPAT) for bone and joint infections: experience from a UK teaching hospital-based service. J Antimicrob Chemother. 2011;66(2):408–15.

    Article  PubMed  CAS  Google Scholar 

  27. Gesser RM, McCarroll KA, Woods GL. Evaluation of outpatient treatment with ertapenem in a double blind controlled clinical trial of complicated skin/skin structure infections. J Infect. 2004;48(1):32–8.

    Article  PubMed  Google Scholar 

  28. Rehm S, Campion M, Katz DE, Russo R, Boucher HW. Community-based outpatient parenteral antimicrobial therapy (CoPAT) for Staphylococcus aureus bacteraemia with or without infective endocarditis: analysis of the randomized trial comparing daptomycin with standard therapy. J Antimicrob Chemother. 2009;63(5):1034–42.

    Article  PubMed  CAS  Google Scholar 

  29. Amodeo MR, Clulow T, Lainchbury J, Murdoch DR, Gallagher K, Dyer A, et al. Outpatient intravenous treatment for infective endocarditis: safety, effectiveness and one-year outcomes. J Infect. 2009;59(6):387–93.

    Article  PubMed  Google Scholar 

  30. Seaton RA, Bell E, Gourlay Y, Semple L. Nurse-led management of uncomplicated cellulitis in the community: evaluation of a protocol incorporating intravenous ceftriaxone. J Antimicrob Chemother. 2005;55(5):764–7.

    Article  PubMed  CAS  Google Scholar 

  31. Seaton RA, Sharp E, Bezlyak V, Weir CJ. Factors associated with outcome and duration of therapy in outpatient parenteral antibiotic therapy (OPAT) patients with skin and soft-tissue infections. Int J Antimicrob Agents. 2011;38(3):243–8.

    Article  PubMed  CAS  Google Scholar 

  32. Nathwani D. The management of skin and soft tissue infections: outpatient parenteral antibiotic therapy in the United Kingdom. Chemotherapy. 2001;47(Suppl 1):17–23.

    Article  PubMed  CAS  Google Scholar 

  33. Tice AD. Pharmacoeconomic considerations in the ambulatory use of parenteral cephalosporins. Drugs. 2000;59(Suppl 3):29–35. (discussion 47–49).

    Article  PubMed  Google Scholar 

  34. Eron LJ, Goldenberg RI, Poretz DM. Combined ceftriaxone and surgical therapy for osteomyelitis in hospital and outpatient settings. Am J Surg. 1984;148(4A):1–4.

    PubMed  CAS  Google Scholar 

  35. Mauceri AA. Treatment of bone and joint infections utilizing a third-generation cephalosporin with an outpatient drug delivery device. HIAT Study Group. Am J Med. 1994;97(2A):14–22.

    Article  PubMed  CAS  Google Scholar 

  36. Tice AD, Hoaglund PA, Shoultz DA. Risk factors and treatment outcomes in osteomyelitis. J Antimicrob Chemother. 2003;51(5):1261–8.

    Article  PubMed  CAS  Google Scholar 

  37. Francioli PB. Ceftriaxone and outpatient treatment of infective endocarditis. Infect Dis Clin North Am. 1993;7(1):97–115.

    PubMed  CAS  Google Scholar 

  38. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. JAMA. 1992;267(2):264–7.

    Article  PubMed  CAS  Google Scholar 

  39. Cervera C, del Rio A, Garcia L, Sala M, Almela M, Moreno A, et al. Efficacy and safety of outpatient parenteral antibiotic therapy for infective endocarditis: a ten-year prospective study. Enferm Infecc Microbiol Clin. 2011;29(8):587–92.

    Article  PubMed  Google Scholar 

  40. Larioza J, Heung L, Girard A, Brown RB. Management of infective endocarditis in outpatients: clinical experience with outpatient parenteral antibiotic therapy. South Med J. 2009;102(6):575–9.

    Article  PubMed  Google Scholar 

  41. Popescu GA. The long journey of outpatient parenteral antibiotic therapy in infective endocarditis: from idea to clinical guidelines. South Med J. 2009;102(6):559–60.

    Article  PubMed  Google Scholar 

  42. Tice AD. Safety of outpatient parenteral antimicrobial therapy for endocarditis. Clin Infect Dis. 2002;34(3):419–20.

    Article  PubMed  Google Scholar 

  43. Monteiro CA, Cobbs CG. Outpatient management of infective endocarditis. Curr Infect Dis Rep. 2001;3(4):319–27.

    Article  PubMed  Google Scholar 

  44. Andrews MM, von Reyn CF. Patient selection criteria and management guidelines for outpatient parenteral antibiotic therapy for native valve infective endocarditis. Clin Infect Dis. 2001;33(2):203–9.

    Article  PubMed  CAS  Google Scholar 

  45. Steele RW. Ceftriaxone therapy of meningitis and serious infections. Am J Med. 1984;77(4C):50–3.

    PubMed  CAS  Google Scholar 

  46. Martin E. Once-daily administration of ceftriaxone in the treatment of meningitis and other serious infections in children. Eur J Clin Microbiol. 1983;2(5):509–15.

    Article  PubMed  CAS  Google Scholar 

  47. Faella F, Pagliano P, Fusco U, Attanasio V, Conte M. Combined treatment with ceftriaxone and linezolid of pneumococcal meningitis: a case series including penicillin-resistant strains. Clin Microbiol Infect. 2006;12(4):391–4.

    Article  PubMed  CAS  Google Scholar 

  48. O’Connell S. Lyme borreliosis: current issues in diagnosis and management. Curr Opin Infect Dis. 2010;23(3):231–5.

    Article  PubMed  Google Scholar 

  49. Ljostad U, Skogvoll E, Eikeland R, Midgard R, Skarpaas T, Berg A, et al. Oral doxycycline versus intravenous ceftriaxone for European Lyme neuroborreliosis: a multicentre, non-inferiority, double-blind, randomised trial. Lancet Neurol. 2008;7(8):690–5.

    Article  PubMed  Google Scholar 

  50. Mogabgab WJ. Single-dose oral temafloxacin versus parenteral ceftriaxone in the treatment of gonococcal urethritis/cervicitis. Am J Med. 1991;91(6A):145S–9S.

    Article  PubMed  CAS  Google Scholar 

  51. Reusser P, Serex P. Outpatient treatment of gonorrhea with ceftriaxone. J Chemother. 1989;1(4 Suppl):895–6.

    PubMed  CAS  Google Scholar 

  52. Collier AC, Judson FN, Murphy VL, Leach LA, Root CJ, Handsfield HH. Comparative study of ceftriaxone and spectinomycin in the treatment of uncomplicated gonorrhoea in women. Am J Med. 1984;77(4C):68–72.

    PubMed  CAS  Google Scholar 

  53. Chisholm SA, Alexander S, Desouza-Thomas L, Maclure-Webster E, Anderson J, Nichols T, et al. Emergence of a Neisseria gonorrhoeae clone showing decreased susceptibility to cefixime in England and Wales. J Antimicrob Chemother. 2011;66(11):2509–12.

    Article  PubMed  CAS  Google Scholar 

  54. Carannante A, Prignano G, Cusini M, Matteelli A, Dal Conte I, Ghisetti V, et al. Cefixime and ceftriaxone susceptibility of Neisseria gonorrhoea in Italy from 2006 to 2010. Clin Microbiol Infect. 2011.

  55. Martin I, Jayaraman G, Wong T, Liu G, Gilmour M. Trends in antimicrobial resistance in Neisseria gonorrhoeae isolated in Canada: 2000–2009. Sex Transm Dis. 2011;38(10):892–8.

    Article  PubMed  CAS  Google Scholar 

  56. Butler T. Treatment of typhoid fever in the 21st century: promises and shortcomings. Clin Microbiol Infect. 2011;17(7):959–63.

    Article  PubMed  CAS  Google Scholar 

  57. Beeching NJ, Parry CM. Outpatient treatment of patients with enteric fever. Lancet Infect Dis. 2011;11(6):419–21.

    Article  PubMed  Google Scholar 

  58. White B, Coia JE, Sykes C, Mather H, Seaton RA. Enteric fever in returning travellers: role of outpatient parenteral antibiotic therapy. J Infect. 2012;64(2):242–5.

    Article  PubMed  CAS  Google Scholar 

  59. Fekety FR. Safety of parenteral third-generation cephalosporins. Am J Med. 1990;88(4A):38S–44S.

    Article  PubMed  CAS  Google Scholar 

  60. Bijie H, Kulpradist S, Manalaysay M, Soebandrio A. In vitro activity, pharmacokinetics, clinical efficacy, safety and pharmacoeconomics of ceftriaxone compared with third and fourth generation cephalosporins: review. J Chemother. 2005;17(1):3–24.

    PubMed  CAS  Google Scholar 

  61. Lamb HM, Ormrod D, Scott LJ, Figgitt DP. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections. Drugs. 2002;62(7):1041–89.

    Article  PubMed  CAS  Google Scholar 

  62. Boggs SR, Cunnion KM, Raafat RH. Ceftriaxone-induced hemolysis in a child with lyme arthritis: a case for antimicrobial stewardship. Pediatrics. 2011;128(5):e1289–92.

    Article  PubMed  Google Scholar 

  63. Kapur G, Valentini RP, Mattoo TK, Warrier I, Imam AA. Ceftriaxone induced hemolysis complicated by acute renal failure. Pediatr Blood Cancer. 2008;50(1):139–42.

    Article  PubMed  Google Scholar 

  64. Imam SN, Wright K, Bhoopalam N, Choudhury A. Hemolytic anemia from ceftriaxone in an elderly patient: a case report. J Am Med Dir Assoc. 2008;9(8):610–1.

    Article  PubMed  Google Scholar 

  65. Goyal M, Donoghue A, Schwab S, Hasbrouck N, Khojasteh S, Osterhoudt K. Severe hemolytic crisis after ceftriaxone administration. Pediatr Emerg Care. 2011;27(4):322–3.

    Article  PubMed  Google Scholar 

  66. Andersohn F, Konzen C, Garbe E. Systematic review: agranulocytosis induced by nonchemotherapy drugs. Ann Intern Med. 2007;146(9):657–65.

    PubMed  Google Scholar 

  67. Duncan CJ, Evans TJ, Seaton RA. Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy. J Antimicrob Chemother. 2010;65(11):2483–4.

    Article  PubMed  CAS  Google Scholar 

  68. Patel R, Grogg KL, Edwards WD, Wright AJ, Schwenk NM. Death from inappropriate therapy for Lyme disease. Clin Infect Dis. 2000;31(4):1107–9.

    Article  PubMed  CAS  Google Scholar 

  69. Zishka PA, Douglas JM Jr. Immediate hypersensitivity reaction to single-dose parenteral ceftriaxone therapy for gonorrhea. Sex Transm Dis. 1991;18(1):26–7.

    Article  PubMed  CAS  Google Scholar 

  70. Pichichero ME. Use of selected cephalosporins in penicillin-allergic patients: a paradigm shift. Diagn Microbiol Infect Dis. 2007;57(3 Suppl):13S–8S.

    Article  PubMed  Google Scholar 

  71. Rienstra M, Bonten MJ, Gaillard CA. Ceftriaxone-associated biliary pseudolithiasis. Neth J Med. 2009;67(3):113–4.

    PubMed  CAS  Google Scholar 

  72. Karakitsos D, Poularas J, Samonis G, Karabinis A. Ceftriaxone-associated reversible biliary sludge in a critical care patient. Acta Anaesthesiol Scand. 2008;52(8):1171–2.

    Article  PubMed  CAS  Google Scholar 

  73. Martin E, Fanconi S, Kalin P, Zwingelstein C, Crevoisier C, Ruch W, et al. Ceftriaxone-bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr. 1993;152(6):530–4.

    Article  PubMed  CAS  Google Scholar 

  74. Mohkam M, Karimi A, Gharib A, Daneshmand H, Khatami A, Ghojevand N, et al. Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol. 2007;22(5):690–4.

    Article  PubMed  Google Scholar 

  75. Kimata T, Kaneko K, Takahashi M, Hirabayashi M, Shimo T, Kino M. Increased urinary calcium excretion caused by ceftriaxone: possible association with urolithiasis. Pediatr Nephrol. 2012;27(4):605–9.

    Google Scholar 

  76. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis. 2008;46(Suppl 1):S19–31.

    Article  PubMed  Google Scholar 

  77. Kuntz JL, Chrischilles EA, Pendergast JF, Herwaldt LA, Polgreen PM. Incidence of and risk factors for community-associated Clostridium difficile infection: a nested case-control study. BMC Infect Dis. 2011;11:194.

    Article  PubMed  Google Scholar 

  78. Barr DA, Semple L, Seaton RA. Outpatient parenteral antimicrobial therapy (OPAT) in a teaching hospital-based practice: a retrospective cohort study describing experience and evolution over 10 years. Int J Antimicrob Agents. 2012;39(5):407-13.

    Google Scholar 

  79. Schirmer PL, Deresinski SC. Ceftobiprole: a new cephalosporin for the treatment of skin and skin structure infections. Expert Rev Anti Infect Ther. 2009;7(7):777–91.

    Article  PubMed  CAS  Google Scholar 

  80. Laudano JB. Ceftaroline fosamil: a new broad-spectrum cephalosporin. J Antimicrob Chemother. 2011;66(Suppl 3):iii11–iii18.

    Google Scholar 

  81. Struelens MJ, Monnet DL. Prevention of methicillin-resistant Staphylococcus aureus infection: is Europe winning the fight? Infect Control Hosp Epidemiol. 2010;31(Suppl 1):S42–4.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

CJAD is supported by a Wellcome Trust Research Training Fellowship.

Funding

None.

Conflicts of interest

RAS has previously received speaker fees, consultancy and research funding from Novartis and Pfizer.

Author information

Authors and Affiliations

  1. Brownlee Centre for Infection, Tropical Medicine and Counselling, Gartnaval Hospital, Glasgow, G12 0YN, UK

    Christopher J. A. Duncan, David A. Barr & R. Andrew Seaton

  2. Sir William Dunn School of Pathology, University of Oxford, South Parks Road, Oxford, OX1 3RE, UK

    Christopher J. A. Duncan

Authors
  1. Christopher J. A. Duncan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. David A. Barr
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Andrew Seaton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher J. A. Duncan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Duncan, C.J.A., Barr, D.A. & Seaton, R.A. Outpatient parenteral antimicrobial therapy with ceftriaxone, a review. Int J Clin Pharm 34, 410–417 (2012). https://doi.org/10.1007/s11096-012-9637-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11096-012-9637-z

Keywords

Search

Navigation